Detail akcie Gensight online

Business Summary: Gensight Biologics SA is a France-based biopharmaceutical company. The Company develops and commercializes gene therapy-based treatments of retinal degenerative diseases. It develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The Company intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Gensight Biologics SA revenues increased 18% to EUR1.5M. Net loss applicable to common stockholders decreased 47% to EUR14M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development of novel therapies segment loss decrease of 47% to EUR15.8M.